A detailed history of Verition Fund Management LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 22,606 shares of ERAS stock, worth $61,036. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,606
Holding current value
$61,036
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.79 - $2.63 $40,464 - $59,453
22,606 New
22,606 $53,000
Q1 2023

May 15, 2023

BUY
$2.74 - $4.44 $120,475 - $195,222
43,969 New
43,969 $132,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $330M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.